Latest News

Arun Srivastava Co-Chairs 3rd International Human Gene Therapy Conference

Mar 23, 2026

President and co-founder of nAAVigen Therapeutics Arun Srivastava delivered two presentations (Development of Capsid- and Genome-Modified NextGen AAV Vectors; Nuclease-Free Gene Editing With AAV-B19 Hybrid and Chimeric Vectors) at the 3rd International Human Gene Therapy Conference held March 23-25 in Boston, Massachusetts.

nAAvigen President Arun Srivastava interview in Cell & Gene

Oct 27, 2025

In conversation with Cell & Gene, President and co-founder of nAAVigen Therapeutics Arun Srivastava explains the science behind the company’s “nuclease-free” approach to epigenetic editing - and its potential to address the limitations of current epigenetic editing technologies.

nAAvigen Therapeutics presents at 2nd Global Cell & Gene Therapy Summit

Jul 7, 2025

President and co-founder of nAAVigen Therapeutics Arun Srivastava presented a paper on the development of genome-modified NextGen AAV vectors at the 2nd Global Cell & Gene Therapy Summit held July 7-9 in Orlando, Florida.